Brief: Isofol Medical Presents Gene Expression Results From Completed Phase I/IIa ISO-CC-005 Study
Jan 15 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST :
* PRESENTS GENE EXPRESSION RESULTS FROM COMPLETED PHASE
I/IIA
ISO-CC-005 STUDY AT ASCO-GI 2021
* RESULT FROM PHASE I/IIA ISO-CC-005-STUDY WHICH SHOWS
CORRELATION
BETWEEN CLINICAL BENEFIT AND GENE EXPRESSION IN PATIENTS WITH
CANCER TREATED WITH 5-FU-BASED CHEMOTHERAPY IN COMBINATION WITH
ARFOLITIXORIN
Source text for Eikon: ID:nWkr1BDGfB
Further company coverage: ISOFOL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million
Brief: Isofol Medical Announces Bfarm Approval Of Optimized Phase Ib/Ii Study Design
Brief: Isofol Gets Gross Proceeds Of SEK 18.9 Mln In Connection With Exercise Of Warrants And Guarantee Commitments
Brief: Isofol Secures License Rights For Arfolitixorin In Autism